Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Truist Securities analyst Supawat Thongthip assumes Arcus Biosciences (NYSE:RCUS) with a Buy rating and raises Price Target to $35.
Truist Securities analyst Supawat Thongthip assumes Arcus Biosciences (NYSE:RCUS) with a Buy rating and raises Price Target to $35.